MUMBAI — For lung cancer patients in India, a treatment that once meant sitting for an hour or more with an IV drip can now be finished in the time it takes to brew a pot of coffee.
Roche Pharma India has launched Tecentriq SC, a subcutaneous version of the immunotherapy atezolizumab. The shot takes roughly seven minutes. The intravenous version of the same drug typically requires 30 to 60 minutes, plus setup and monitoring time.
The difference is not just convenience. It is a shift in how the healthcare system can deploy a scarce resource. Tecentriq SC, according to the company, can treat up to five patients in the time it once took to treat one patient on intravenous infusion. For a country where oncology infrastructure is stretched thin, that math matters.
India faces a rising burden of lung cancer, and treatment options have historically lagged behind those in the West. Immunotherapy drugs like atezolizumab work by helping the body’s own immune system recognize and attack cancer cells. But the standard way to deliver them — through a vein — ties patients to a hospital chair for long stretches. It also ties up nursing staff and infusion centers.
The new formulation changes that. Patients get a single injection under the skin. The drug is formulated with a protein called hyaluronidase, which allows larger volumes of liquid to be absorbed quickly into the tissue. That is the technical trick behind the seven-minute timeline.
For patients, the implications go beyond the clock. Shorter visits mean less time off work for caregivers. Less need to travel long distances to a major hospital. Lower indirect costs. The company cited global data showing that four out of five patients prefer the subcutaneous shot over intravenous delivery. That preference came out of the IMscin002 study, presented at the European Lung Cancer Congress.
The logic is straightforward. A patient who can get treated in a clinic closer to home, and be done before lunch, faces fewer disruptions to daily life. That matters for a disease where treatment often stretches over months or years.
This is not the first subcutaneous immunotherapy, but it is the first for lung cancer in India. The drug itself — atezolizumab, sold under the brand name Tecentriq — has been available in IV form for years. Roche already markets it for several cancers worldwide. The subcutaneous version won approval in parts of Europe and the United States before reaching India.
The timing of the India launch reflects both regulatory clearance and a broader push by Roche to expand access in emerging markets. India’s drug regulator approved the subcutaneous formulation earlier this year.
Roche Pharma India announced the launch in Mumbai on June 9. The company framed it as a breakthrough, but the real test will be uptake. Doctors must be trained. Hospitals must adjust workflows. Reimbursement and pricing — not detailed in the announcement — will determine how many patients actually get the shot.
Still, the direction is clear. The treatment experience for lung cancer patients in India is about to get faster. Whether that speed translates into better outcomes depends on how quickly the system adapts. The medical community will be watching.
